Doseology Sciences, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Kareem Baalbaki
- Full Time Employees
- 5
- Sector
- Health technology
- Industry
- Pharmaceuticals: other
- Address
- 9-3151 Lakeshore Road Kelowna BC Canada V1W 3S9
- IPO Date
- Nov 21, 2021
- Website
- doseology.com
- Similar Companies
- Business
- Doseology Sciences Inc. (CSE: MOOD) is a British Columbia-based life sciences company focused on developing and commercializing functional mushroom products and nutraceuticals targeting mental health and wellness. Through its subsidiary Dose Labs Inc., the company researches, develops, and sells medicinal mushroom products including adaptogenic tinctures, powders, and herbal supplements featuring lion’s mane, reishi, shiitake, maitake, turkey tail, royal sun, and blends with botanicals such as ginger, turmeric, and yerba mate; these address mood and depression, attention and focus, sleep and recovery, anxiety, cognition, immunity, and stress reduction, available online via doseology.com, e-commerce platforms, retail chains like Healthy Planet, and distributors primarily in Canada with U.S. expansion. Founded in 2019 and headquartered at 9-3151 Lakeshore Road, Kelowna, British Columbia, Doseology operates in the biotechnology and healthcare sectors, serving consumers seeking natural mental health solutions amid the functional mushroom market's growth. Recent developments include the November 2025 securing of a strategic manufacturing agreement via its Florida-based wholly owned subsidiary Doseology USA Inc. for FDA-registered, GMP-certified production of oral stimulant pouches with nicotine, caffeine, and nootropics; the March 2025 launch of Doseology USA Inc. to enter the U.S. modern oral stimulant market; completion of the Feed That Brain acquisition; appointment of Joseph Mimran as strategic advisor and new executives including CEO Christopher Jackson in 2025 and a new CFO; and a May 2023 share consolidation.
Company News
Doseology Announces Resignation of Director
Doseology Announces Director and Officer Changes; Completes Shares-for-Debt Settlement
Doseology Announces Proposed Shares-for-Debt Settlement and Resignation of Director
Doseology Announces $2M Financing to Accelerate Commercialization of Oral Stimulant Pouch Platform
Doseology Uplists to OTCQB as DOSEF, Expanding U.S. Investor Access to the Emerging Oral Stimulant Pouch Category
Doseology Launches Feed That Brain® Oral Stimulant Pouches in the U.S. Through Direct-to-Consumer Pilot
Doseology Appoints Larry Latowsky as Executive Chairman of the Board of Directors
Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market
Doseology Begins Pilot Production of Caffeine-Based Energy Pouches as Feed That Brain® Enters Oral Stimulant Format
2026 Asset Growth: Why Federal Compliance Is the New Metric
The Compliance Imperative: Regulatory Moats Driving 2026 Asset Re-Ratings
Doseology Files Annual Information Form (AIF), Strengthening Public Disclosure Record AIF Filing Enhances Transparency and Provides Consolidated Disclosure for Investors
Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise
The "New Vice" Economy: 5 Stocks Profiting from the Shift to Clean Fuel
Doseology Completes Extensive North American Diligence, Securing Strategic Manufacturing Agreement via U.S. Subsidiary Doseology USA Inc.
Doseology Appoints Patrick W. Sills as Strategic Go-to-Market Advisor
Doseology Closes $750,000 Non-Brokered Private Placement
CSE Bulletin: Consolidation - Doseology Sciences Inc. (MOOD)